Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(7):494-496; doi:10.1093/jnci/93.7.494
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 7, 494-496, April 4, 2001
© 2001 Oxford University Press

NEWS

Lymphoma Rate Rise Continues to Baffle Researchers

Ken Garber

Back in 1991, the National Cancer Institute sponsored a 2-day workshop to ponder the mysterious "emerging epidemic" of non-Hodgkin’s lymphoma. A decade later, the mystery persists, and NHL cases continue to rise. "It’s been quite dramatic," says pathologist Dennis Weisenburger, M.D., of the University of Nebraska. "Something is clearly going on, and we don’t understand it."

Since 1950, NHL has increased in frequency by about 4% a year. Overall, between 1973 and 1997, incidence grew 81%. This year 56,200 Americans will be diagnosed with NHL, which is now the fifth most common non-skin cancer in the United States. "It is remarkable how NHL has gone from being what we would consider a rare disease ... to what we consider in the moderate . . . [Full Text of this Article]

Causal Chain?

Risk Factors?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J EpidemiolHome page
S. Bahl, M. Cotterchio, N. Kreiger, and N. Klar
Antidepressant Medication Use and Non-Hodgkin's Lymphoma Risk: No Association
Am. J. Epidemiol., September 15, 2004; 160(6): 566 - 575.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. W. Blayney, M. L. LeBlanc, T. Grogan, E. R. Gaynor, R. A. Chapman, C. H. Spiridonidis, S. A. Taylor, S. I. Bearman, T. P. Miller, and R. I. Fisher
Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349)
J. Clin. Oncol., July 1, 2003; 21(13): 2466 - 2473.
[Abstract] [Full Text] [PDF]